List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
A newly discovered RNA molecule, EUDAL, helps oral cancers survive chemotherapy by keeping a key growth protein permanently active. Researchers say targeting EUDAL could predict resistance and improve treatment outcomes.
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
Researchers in China have discovered how glioblastoma adapts to low-oxygen conditions – revealing a new treatment strategy that combines an orphan drug with standard chemotherapy to overcome resistance.
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
Researchers at Sutter’s California Pacific Medical Center have discovered a potential new treatment strategy for melanoma patients who stop responding to immunotherapy.
Circulating tumour cell (CTC)-derived organoids are changing cancer research, providing scientists with a powerful tool for studying drug resistance and informing the development of new personalised therapies.
